Discounted Cash Flow Rating

Sell

Return on Equity Rating

Sell

Debt to Equity Rating

Neutral

Price to Earnings Rating

Strong Buy

Analyst Rating

Neutral

Upgrade To View Simple Moving Average Rating

Upgrade

Upgrade To Get Access

Upgrade To View Exponential Moving Average Rating

Upgrade

Upgrade To Get Access

Upgrade To View Relative Strength Index Rating

Upgrade

Upgrade To Get Access

Upgrade To View Standard Deviation Rating

Upgrade

Upgrade To Get Access

Upgrade To View Williams %R Rating

Upgrade

Upgrade To Get Access

Upgrade To View Average Directional Index Rating

Upgrade

Upgrade To Get Access

Upgrade To View Insider Trading Rating

Upgrade

Upgrade To Get Access

Wall Street Data Solutions Rating

Neutral

B

Caribou Biosciences, Inc. Common Stock (CRBU)

Biological Products, (no Disgnostic Substances)

https://www.cariboubio.com

Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies.

2929 7TH STREET, SUITE 105
BERKELEY, CA

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

07/23/2021

Market Cap

189,310,066

Shares Outstanding

88,430,000

Weighted SO

88,431,136

Total Employees

N/A

Upcoming Earnings

08/13/2024

Similar Tickers

NTLA --.--%

EDIT --.--%

CRSP --.--%

VERV --.--%

BEAM --.--%

BEAM --.--%

FATE --.--%

PRME --.--%

PRME --.--%

Beta

2.3020

Last Div

0.0000

Range

1.5-8.33

Chg

0.0150

Avg Vol

2458383

Mkt Cap

189310066

Exch

NASDAQ

Country

US

Phone

510 982 6030

DCF Diff

5.6255

DCF

-0.0255

Div Yield

0.0000

P/S

5.7171

EV Multiple

-1.2885

P/FV

0.6096

Div Yield %

0.0000

P/E

-1.5333

PEG

-0.0967

Payout

0.0000

Current Ratio

8.7539

Quick Ratio

8.7539

Cash Ratio

1.2237

DSO

32.1427

DIO

0.0000

Op Cycle

32.1427

DPO

208.6176

CCC

-176.4749

Gross Margin

0.8295

Op Margin

-4.2756

Pretax Margin

-3.7220

Net Margin

-3.7278

Eff Tax Rate

0.0170

ROA

-0.3310

ROE

-0.3476

ROCE

-0.4140

NI/EBT

1.0016

EBT/EBIT

0.8705

EBIT/Rev

-4.2756

Debt Ratio

0.0733

D/E

0.0880

LT Debt/Cap

0.0760

Total Debt/Cap

0.0809

Int Coverage

-46.0866

CF/Debt

-4.3996

Equity Multi

1.2012

Rec Turnover

11.3556

Pay Turnover

1.7496

Inv Turnover

0.0000

FA Turnover

0.8074

Asset Turnover

0.0888

OCF/Share

-1.3309

FCF/Share

-1.4496

Cash/Share

2.8962

OCF/Sales

-3.6311

FCF/OCF

1.0891

CF Coverage

-4.3996

ST Coverage

-66.7607

CapEx Coverage

-11.2181

Div&CapEx Cov

-11.2181

P/BV

0.6096

P/B

0.6096

P/S

5.7171

P/E

-1.5333

P/FCF

-1.4456

P/OCF

-1.5741

P/CF

-1.5741

PEG

-0.0967

P/S

5.7171

EV Multiple

-1.2885

P/FV

0.6096

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. Jul 25, 23:35 CARIBOU ALERT: Bragar Eagel & Squire, P.C. is Investigating Caribou Biosciences, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm GlobeNewswire Inc. Feb 16, 14:15 CRBU IMPORTANT DEADLINE: ROSEN, LEADING TRIAL ATTORNEYS, Encourages Caribou Biosciences, Inc. Investors to Secure Counsel Before Important February 24 Deadline in Securities Class Action - CRBU GlobeNewswire Inc. Feb 11, 02:14 ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Caribou Biosciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - CRBU GlobeNewswire Inc. Feb 07, 23:08 ROSEN, A LEADING NATIONAL FIRM, Encourages Caribou Biosciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - CRBU GlobeNewswire Inc. Feb 02, 21:00 CRBU INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Caribou Biosciences, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit GlobeNewswire Inc. Jan 25, 18:31 TOP RANKED ROSEN LAW FIRM Encourages Caribou Biosciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - CRBU GlobeNewswire Inc. Jan 23, 02:00 Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Capri, Caribou, Nextracker, and Transocean and Encourages Investors to Contact the Firm GlobeNewswire Inc. Jan 19, 18:39 ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Caribou Biosciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - CRBU GlobeNewswire Inc. Jan 17, 00:44 ROSEN, TOP-RANKED INVESTOR COUNSEL, Encourages Caribou Biosciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - CRBU GlobeNewswire Inc. Jan 14, 01:42 Caribou Biosciences, Inc. Shareholders are Encouraged to Contact Robbins LLP for Information About the Lead Plaintiff Deadline in the CRBU Class Action GlobeNewswire Inc. Jan 13, 00:05 Caribou Biosciences Initiates the CB-010 GALLOP Phase 1 Trial in Lupus and Provides Outlook for Multiple Clinical Datasets in 2025 GlobeNewswire Inc. Jan 12, 21:28 ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Caribou Biosciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - CRBU GlobeNewswire Inc. Jan 10, 02:22 ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Caribou Biosciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - CRBU GlobeNewswire Inc. Jan 04, 02:01 ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Caribou Biosciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - CRBU GlobeNewswire Inc. Dec 29, 00:59 ROSEN, A TRUSTED FIRM, Encourages Caribou Biosciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - CRBU GlobeNewswire Inc. Jun 02, 23:00 Caribou Biosciences Presents Encouraging Clinical Data from CB-010 ANTLER Phase 1 Trial in Second-line LBCL Patients at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting The Motley Fool Jan 15, 08:45 3 Biotech Stocks You Can Buy and Hold for the Next Decade The Motley Fool Jan 15, 08:45 3 Biotech Stocks You Can Buy and Hold for the Next Decade GlobeNewswire Inc. Jan 07, 11:00 Caribou Biosciences Appoints Tim Kelly as Chief Technology Officer and Highlights Multiple Clinical Catalysts Expected in 2024 GlobeNewswire Inc. Jan 07, 11:00 Caribou Biosciences Appoints Tim Kelly as Chief Technology Officer and Highlights Multiple Clinical Catalysts Expected in 2024

Revenue Product Segmentation